The Atlas Arteria Group (ASX: ALX) share price is in focus after the company lodged its Supplementary Target's Statement rejecting IFM's takeover offer, which independent directors say undervalues the business and is below the current market price.
Image source: Getty Images
What did Atlas Arteria report?
- The independent directors unanimously recommend Atlas Arteria securityholders reject the $4.75 per security takeover offer from IFM.
- The Independent Expert's Report values Atlas Arteria at $5.39–$6.20 per security, higher than the current offer.
- The offer price is below Atlas Arteria's recent closing price of $5.04 (as at 1 June 2026).
- The IFM offer remains highly conditional and may extend up to 12 months.
- Bidder retains the right to increase the offer up to $5.10 within 12 months after the offer closes.
What else do investors need to know?
The Supplementary Target's Statement responds directly to IFM's Third Supplementary Bidder's Statement, reiterating that the offer is "too low, opportunistic and highly conditional". Atlas Arteria's independent directors maintain that the terms do not provide an appropriate premium for control or reflect the long-term value of its international toll road portfolio.
The Board highlights that accepting the offer now would prevent shareholders from selling on market for potentially higher prices during the lengthy offer period. Securityholders are encouraged to read the full Target's Statement and seek independent advice if considering their options.
What's next for Atlas Arteria?
Atlas Arteria's board will continue actively engaging with shareholders and monitoring developments related to IFM's bid. Investors can expect ongoing updates if circumstances change or if a revised offer is made.
The company also remains focused on disciplined management and sustainable long-term value creation through its established portfolio of toll road assets in France, Germany, and the United States.
Atlas Arteria share price snapshot
Over the past 12 months, Atlas Arteria shares have declined 5%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.
